Science First, Finance Second: FP&A for Clinical-Stage Biotech
Biotech finance teams are built around the science and that's exactly where leadership focus belongs. But as your pipeline advances and your investor base grows, the bar for financial rigor rises fast. When board members and investors start asking about burn, variance, and runway, most clinical-stage finance functions aren't ready to answer cleanly. Management ends up estimating in real time, or twisting itself into a pretzel to get to a number. That's not a people problem. It's an infrastructure problem.
This webinar walks through the six most common financial gaps CFGI sees at clinical-stage biotech companies — and how finance teams are closing them to build the visibility and credibility their boards expect.
In this webinar, you'll learn how to:
Build a GL-integrated budget that replaces your Excel-only model aligning your budget basis to your general ledger and financial statement roll-up so budget-to-actual comparisons reflect reality, not a translation exercise between two different frameworks
Create a complete trial cost budget that captures every phase of your expected programs — including the line items most teams miss until they're heading into a financing round or board review and realize the gaps too late
Stand up a budget-to-actual monitoring process that gives management real visibility — not just a variance report produced after the close, but a rhythm that flags issues early and keeps the business running against plan
Build a 13-week cash flow forecast your CFO and board can rely on — so runway questions have a precise, defensible answer instead of a back-of-envelope estimate
Develop an integrated three-statement model that connects your income statement, balance sheet, and cash flow — unlocking scenario planning and giving investors the financial picture they need to make decisions alongside you
Who should attend: CFOs, VPs of Finance, Controllers, and FP&A leaders at clinical-stage and pre-commercial biotech companies.
